Publications Database

Aman M. G. et al. (2005)

Acute and long-term safety and tolerability of risperidone in children with autism.

Journal of Child and Adolescent Psychopharmacology

15(6), pp. 869-884

Read Abstract (New Window)

Aman M. G. et al. (2008)

Cognitive effects of risperidone in children with autism and irritable behavior.

Journal of Child and Adolescent Psychopharmacology

18(3), pp. 227-236

Read Abstract (New Window) Read Full (New Window)

Aman M. G. et al. (2015)

Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial.

Journal of Child and Adolescent Psychopharmacology

August, 25(6), pp. 482-493.

Read Abstract (New Window) Read Full (New Window)

Anderson G. M. et al. (2007)

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

February, 61(4), pp. 545-550.

Read Abstract (New Window)

Arnold L. E. et al. (2000)

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network.

Journal of Autism and Developmental Disorders

April, 30(2), pp. 99–111

Read Abstract (New Window)

Brentani H. et al. (2013)

Autism spectrum disorders: an overview on diagnosis and treatment.

Revista Brasileira de Psiquiatria

35 S 62-72.

Read Abstract (New Window) Read Full (New Window)

Carroll D. et al. (2014)

Examination of aggression and self injury in children with autism spectrum disorders and serious behavioral problems.

Child and Adolescent Psychiatric Clinics of North America

January, 23(1), pp. 57-72.

Read Abstract (New Window)

Erickson C. A. et al. (2014)

STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.

Journal of Autism and Developmental Disorders

44(4), pp. 958-964.

Read Abstract (New Window)

Howes O. D. et al.

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.

Journal of Psychopharmacology

Read Abstract (New Window)

Jahromi L. B. et al. (2009)

Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.

Journal of Autism and Developmental Disorders

39(3), pp. 395-404

Read Abstract (New Window)

Kaplan G. , McCracken J. T. (2012)

Psychopharmacology of autism spectrum disorders.

Pediatric Clinics of North America

59(1), pp. 175-187

Read Abstract (New Window)

King B. H. et al. (2013)

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial.

JAMA Pediatrics

November, 167(11),

Read Abstract (New Window)

King B. H. et al. (2009)

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

Archives of General Psychiatry

66(6), pp. 583-590

Read Abstract (New Window)

Lindsay R. L. et al. (2006)

Dietary status and impact of risperidone on nutritional balance in children with autism: A pilot study.

Journal of Intellectual and Developmental Disability

December, 31(4), pp. 204-209.

Read Abstract (New Window)

Martin A. et al. (2004)

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

American Journal of Psychiatry

161(6), pp. 1125-1127

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. et al. (2014)

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.

Pharmacogenomics

14(3), pp. 295-302.

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. et al. (2002)

Risperidone in children with autism and serious behavioral problems.

New England Journal of Medicine

347(5), pp. 314-321

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. (2005)

Safety issues with drug therapies for autism spectrum disorders.

Journal of Clinical Psychiatry

66 pp. 32-37

Read Abstract (New Window)

McDougle C. J. et al. (2000)

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.

Child and Adolescent Psychiatric Clinics of North America

January, 9(1), pp. 201-224.

Read Abstract (New Window)

McDougle C. J. et al. (2005)

Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology.

American Journal of Psychiatry

162(6), pp. 1142-1148

Read Abstract (New Window) Read Full (New Window)